Axsome Initiates Phase 3 Trial for ADHD Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 26 2026
0mins
Source: Newsfilter
- Trial Launch: Axsome Therapeutics has announced the dosing of the first patient in the FOCUS-3 Phase 3 trial, which aims to evaluate the efficacy and safety of solriamfetol in treating adolescents aged 12 to 18 with ADHD.
- Trial Scale and Design: The FOCUS-3 trial will randomize approximately 468 patients in a 1:1:1 ratio to receive one of two doses of solriamfetol or placebo for six weeks, with the primary endpoint being the change in ADHD Rating Scale total score.
- Widespread ADHD Impact: Approximately 7 million children and 15.5 million adults in the U.S. are affected by ADHD, with the societal excess cost for adult ADHD exceeding $120 billion annually, highlighting the urgent need for effective treatments.
- Drug Background: Solriamfetol is a multi-action drug being developed not only for ADHD but also for other CNS disorders, with Axsome's R&D strategy focused on addressing critical gaps in CNS treatment to enhance patient quality of life.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AXSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AXSM
Wall Street analysts forecast AXSM stock price to fall
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 249.760
Low
153.00
Averages
209.54
High
260.00
Current: 249.760
Low
153.00
Averages
209.54
High
260.00
About AXSM
Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Stocks Outperform S&P 500 in H1 2026
- Moderna's Recovery Potential: Moderna forecasts a revenue growth of up to 10% in 2026 and is awaiting regulatory approval for a new flu vaccine on August 5; despite expectations of a 40% price decline over the next 12 months, the launch of new products presents significant growth opportunities for the company.
- Breakthrough Cancer Drug: Revolution Medicines reported unprecedented survival rates for its cancer drug Daraxonrasib in phase 3 trials and plans to submit for regulatory review; while Wall Street anticipates only a 2% price increase in the coming months, the drug's potential market impact is substantial.
- Axsome's Growth Drivers: Axsome Therapeutics is expected to see a 13% price increase over the next year, driven by the approval of its drugs Auvelity and Symbravo, with ongoing phase 3 trials across five treatment areas that could lead to explosive earnings growth if successful.
- Market Sentiment Shift: Despite overall market pressures from turmoil in Iran and rising oil prices, biotech stocks have thrived as investors shift towards new opportunities, reflecting strong demand and confidence in innovative therapies.
See More
Biotech Companies Reach Critical Turning Point
- Moderna's Recovery Outlook: Moderna anticipates a revenue growth of up to 10% in 2026 and is awaiting potential approval for a flu vaccine on August 5, which could provide new growth momentum, although the market expects a 40% pullback in stock price over the next 12 months.
- Revolution Medicines Breakthrough: Revolution Medicines reported significant results in phase 3 trials for its cancer drug, daraxonrasib, showing a median survival of 13.2 months in previously treated metastatic pancreatic cancer, far exceeding chemotherapy's 6.7 months, with plans to submit for regulatory review, indicating substantial future growth potential.
- Axsome's Growth Potential: Axsome Therapeutics is expected to see a 13% stock price increase over the next 12 months, driven by its drugs Auvelity and Symbravo targeting agitation associated with Alzheimer's and migraines, respectively, while ongoing phase 3 trials could lead to explosive earnings growth if successful.
- Market Dynamics Analysis: Despite the S&P 500's over 9% gain in the first half of 2026, biotech companies like Moderna, Revolution Medicines, and Axsome outperformed, reflecting investor interest in emerging opportunities, which may shift market funds towards these high-potential stocks.
See More
Axsome Therapeutics Shows Significant Growth Potential
- Revenue Growth: Axsome Therapeutics reported a 59% increase in Auvelity revenue to $153 million this quarter, while Sunosi's revenue rose 34% to $33 million, demonstrating strong performance in the CNS drug market and solidifying its market position.
- New Drug Launch Prospects: The company has submitted AXS-12 for narcolepsy regulatory review and is conducting phase three trials for solriamfetol across four indications, indicating that potential new product launches could significantly drive future revenue growth and bolster investor confidence.
- Market Coverage Improvement: Currently, Symbravo's insurance coverage stands at 57%, compared to over 80% for other drugs, and the company is working to enhance this ratio, which is expected to positively impact future sales growth.
- Strong Financial Position: With $305 million in cash reserves, Axsome is well-positioned to fund operations until achieving cash flow positivity, indicating a solid financial foundation for business expansion and new product development.
See More
Axsome's Auvelity Approved for Alzheimer's Agitation Treatment
- Revenue Surge: Axsome's Auvelity generated $153 million in revenue last quarter, marking a 59% increase, indicating strong demand in the Alzheimer's-related drug market and reinforcing the company's position in the CNS disorders sector.
- Sales Force Expansion: To enhance Auvelity's market penetration, Axsome has assembled a sales team of over 600, focusing on promoting the drug to primary care physicians, neurologists, and geriatric specialists, which is expected to significantly boost product awareness and sales.
- New Drug Development: Axsome is advancing AXS-12 for narcolepsy through regulatory review, and solriamfetol is in phase three trials for four indications, which could provide robust support for the company's future revenue growth.
- Strong Cash Position: With $305 million in cash reserves, Axsome is well-positioned to fund operations until achieving cash flow positivity, providing ample financial backing for future expansions and new product launches.
See More
Tarsus Accused of Market Manipulation by Culper Research
- Short Seller Allegations: Culper Research has accused Tarsus Pharmaceuticals of using questionable practices to boost sales of its sole product, XDEMVY, resulting in a 5% drop in stock price on Wednesday, potentially marking its worst day since April.
- Medicare Copay Scheme: Culper claims Tarsus has funded copay assistance for Medicare patients through the HealthWell Foundation, with donations of $5.7 million in 2023 and an expected $31.2 million in 2024, arguing this violates the Anti-Kickback Statute and poses legal risks.
- Inflated Market Size: Tarsus has touted a 25 million patient opportunity for Demodex blepharitis, but a survey indicates only 18% of patients are diagnosed, leading Culper to estimate a true market size closer to 5 million, with peak annual revenues for XDEMVY projected below $800 million.
- Financial Guidance Downgrade: Culper asserts that Tarsus is likely to miss its 2026 guidance, as analysts have underestimated rising patient assistance and other SG&A costs, which could lead to further declines in stock price in the future.
See More
Axosome Initiates Phase 3 Trial for Solriamfetol in ADHD Treatment
- Trial Initiation: Axosome Therapeutics has announced the dosing of the first patient in the Phase 3 FOCUS-3 trial involving 486 ADHD patients, aimed at assessing the safety and efficacy of Solriamfetol over a 6-week period, indicating the company's proactive advancement in ADHD treatment.
- Market Demand: With approximately 7 million children diagnosed with ADHD in the U.S., the potential market opportunity for Solriamfetol is significant, and successful outcomes could lead to substantial revenue growth for the company.
- Drug Mechanism: Solriamfetol acts as a dopamine and norepinephrine reuptake inhibitor, offering multiple mechanisms of action that may provide new treatment options for ADHD, major depressive disorder, and other related conditions, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Stock Performance: Currently trading at $247, up 3.95%, Axosome's stock reflects positive market sentiment regarding its clinical trial progress, which could further bolster investor confidence and company valuation.
See More
Biotech Stocks Outperform S&P 500 in H1 2026
- Moderna's Recovery Potential: Moderna forecasts a revenue growth of up to 10% in 2026 and is awaiting regulatory approval for a new flu vaccine on August 5; despite expectations of a 40% price decline over the next 12 months, the launch of new products presents significant growth opportunities for the company.
- Breakthrough Cancer Drug: Revolution Medicines reported unprecedented survival rates for its cancer drug Daraxonrasib in phase 3 trials and plans to submit for regulatory review; while Wall Street anticipates only a 2% price increase in the coming months, the drug's potential market impact is substantial.
- Axsome's Growth Drivers: Axsome Therapeutics is expected to see a 13% price increase over the next year, driven by the approval of its drugs Auvelity and Symbravo, with ongoing phase 3 trials across five treatment areas that could lead to explosive earnings growth if successful.
- Market Sentiment Shift: Despite overall market pressures from turmoil in Iran and rising oil prices, biotech stocks have thrived as investors shift towards new opportunities, reflecting strong demand and confidence in innovative therapies.
See More
Biotech Companies Reach Critical Turning Point
- Moderna's Recovery Outlook: Moderna anticipates a revenue growth of up to 10% in 2026 and is awaiting potential approval for a flu vaccine on August 5, which could provide new growth momentum, although the market expects a 40% pullback in stock price over the next 12 months.
- Revolution Medicines Breakthrough: Revolution Medicines reported significant results in phase 3 trials for its cancer drug, daraxonrasib, showing a median survival of 13.2 months in previously treated metastatic pancreatic cancer, far exceeding chemotherapy's 6.7 months, with plans to submit for regulatory review, indicating substantial future growth potential.
- Axsome's Growth Potential: Axsome Therapeutics is expected to see a 13% stock price increase over the next 12 months, driven by its drugs Auvelity and Symbravo targeting agitation associated with Alzheimer's and migraines, respectively, while ongoing phase 3 trials could lead to explosive earnings growth if successful.
- Market Dynamics Analysis: Despite the S&P 500's over 9% gain in the first half of 2026, biotech companies like Moderna, Revolution Medicines, and Axsome outperformed, reflecting investor interest in emerging opportunities, which may shift market funds towards these high-potential stocks.
See More
Axsome Therapeutics Shows Significant Growth Potential
- Revenue Growth: Axsome Therapeutics reported a 59% increase in Auvelity revenue to $153 million this quarter, while Sunosi's revenue rose 34% to $33 million, demonstrating strong performance in the CNS drug market and solidifying its market position.
- New Drug Launch Prospects: The company has submitted AXS-12 for narcolepsy regulatory review and is conducting phase three trials for solriamfetol across four indications, indicating that potential new product launches could significantly drive future revenue growth and bolster investor confidence.
- Market Coverage Improvement: Currently, Symbravo's insurance coverage stands at 57%, compared to over 80% for other drugs, and the company is working to enhance this ratio, which is expected to positively impact future sales growth.
- Strong Financial Position: With $305 million in cash reserves, Axsome is well-positioned to fund operations until achieving cash flow positivity, indicating a solid financial foundation for business expansion and new product development.
See More
Axsome's Auvelity Approved for Alzheimer's Agitation Treatment
- Revenue Surge: Axsome's Auvelity generated $153 million in revenue last quarter, marking a 59% increase, indicating strong demand in the Alzheimer's-related drug market and reinforcing the company's position in the CNS disorders sector.
- Sales Force Expansion: To enhance Auvelity's market penetration, Axsome has assembled a sales team of over 600, focusing on promoting the drug to primary care physicians, neurologists, and geriatric specialists, which is expected to significantly boost product awareness and sales.
- New Drug Development: Axsome is advancing AXS-12 for narcolepsy through regulatory review, and solriamfetol is in phase three trials for four indications, which could provide robust support for the company's future revenue growth.
- Strong Cash Position: With $305 million in cash reserves, Axsome is well-positioned to fund operations until achieving cash flow positivity, providing ample financial backing for future expansions and new product launches.
See More
Tarsus Accused of Market Manipulation by Culper Research
- Short Seller Allegations: Culper Research has accused Tarsus Pharmaceuticals of using questionable practices to boost sales of its sole product, XDEMVY, resulting in a 5% drop in stock price on Wednesday, potentially marking its worst day since April.
- Medicare Copay Scheme: Culper claims Tarsus has funded copay assistance for Medicare patients through the HealthWell Foundation, with donations of $5.7 million in 2023 and an expected $31.2 million in 2024, arguing this violates the Anti-Kickback Statute and poses legal risks.
- Inflated Market Size: Tarsus has touted a 25 million patient opportunity for Demodex blepharitis, but a survey indicates only 18% of patients are diagnosed, leading Culper to estimate a true market size closer to 5 million, with peak annual revenues for XDEMVY projected below $800 million.
- Financial Guidance Downgrade: Culper asserts that Tarsus is likely to miss its 2026 guidance, as analysts have underestimated rising patient assistance and other SG&A costs, which could lead to further declines in stock price in the future.
See More
Axosome Initiates Phase 3 Trial for Solriamfetol in ADHD Treatment
- Trial Initiation: Axosome Therapeutics has announced the dosing of the first patient in the Phase 3 FOCUS-3 trial involving 486 ADHD patients, aimed at assessing the safety and efficacy of Solriamfetol over a 6-week period, indicating the company's proactive advancement in ADHD treatment.
- Market Demand: With approximately 7 million children diagnosed with ADHD in the U.S., the potential market opportunity for Solriamfetol is significant, and successful outcomes could lead to substantial revenue growth for the company.
- Drug Mechanism: Solriamfetol acts as a dopamine and norepinephrine reuptake inhibitor, offering multiple mechanisms of action that may provide new treatment options for ADHD, major depressive disorder, and other related conditions, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Stock Performance: Currently trading at $247, up 3.95%, Axosome's stock reflects positive market sentiment regarding its clinical trial progress, which could further bolster investor confidence and company valuation.
See More
